Lannett Launches Venlafaxine ER Tablets And Lidocaine Topical Solution 4%
- Monday, January 6, 2020, 7:10
- Business
- Add a comment
PHILADELPHIA, Jan. 6, 2020 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Venlafaxine Extended Release (ER) Tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4%. The estimated IQVIA market values of Venlafaxine ER Tablets,…
About the Author
adminasapcorp has written 41546 stories on this site.